Moreover, there is good evidence from prostate cancer that the PARPi olaparib is effective in tumours with alterations in RAD51C, RAD51D, CHEK2, PALB2, RAD54L, and BARD1. The gene discussed is RAD51C; the disease is prostate cancer.